Ryan W. Jacobs, MD

A brief review of first-line BTK inhibition in chronic lymphocytic leukemia following the advent of ibrutinib, along with considerations for minimal residual disease testing in this setting.

Expert hematologist-oncologist Sonali Smith, MD, shares a brief overview of chronic lymphocytic leukemia (CLL), highlighting incidence, prognosis, and molecular subsets.

Ryan Jacobs, MD, discusses the implications of next-line treatment strategies following long-term data of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the use of ibrutinib (Imbruvica) in treating chronic graft-versus-host disease in patients with chronic lymphocytic leukemia (CLL).

Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the frontline treatment of patients with chronic lymphocytic leukemia.

Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the efficacy of ibrutinib (Imbruvica) and acalabrutinib (Calquence) in patients with mantle cell lymphoma (MCL).

Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the use of ibrutinib (Imbruvica) in high-risk patients with chronic lymphocytic leukemia (CLL).